Eye disease therapy developer EIR Biopharma files for a $17 million IPO
I'm PortAI, I can summarize articles.
EIR Biopharma, a preclinical biotech focused on eye disease therapies, has filed for a $17 million IPO with the SEC. The San Francisco-based company plans to offer 3.8 million shares priced between $4 and $5. EIR Biopharma develops treatments for conditions like dry age-related macular degeneration and retinal nerve injury, with plans to start human clinical studies in 2027. Founded in 2022, the company aims to list on the NYSE American, with Kingswood Capital Markets as the sole bookrunner.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments